Actively Recruiting
Real-World Study of Control-IQ System Use for Type 1 Diabetes Management Evaluating Safety, Glycemic Control, and Quality of Life in France
Led by Tandem Diabetes Care, Inc. · Updated on 2026-10-14
350
Participants Needed
25
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the ongoing safety, glycemic control, quality of life, and usage rate of the Control-IQ System in people with type 1 diabetes in France. This post-market surveillance study aims to monitor severe metabolic complications such as severe hypoglycemia and diabetic ketoacidosis over 12 months of real-world use. It is a single-arm, prospective cohort study that includes all approved populations using the system. Participants will use the tslim X2 insulin pump with Control-IQ technology combined with a Dexcom G6 or G7 continuous glucose monitoring sensor. They will follow standard care and continue use of the system for at least 12 consecutive months after enrollment. The study gathers data on device performance, patient satisfaction, usability, and quality of life throughout this period. During the study, participants will provide clinical data including HbA1c results from up to 4 months prior and during the study period. They will complete questionnaires about treatment satisfaction, system usability, quality of life, and fear of hypoglycemia. Researchers will measure rates of diabetic ketoacidosis and severe hypoglycemia, time spent in target glucose ranges, and system usage. The total participation duration is 12 months, with safety and device use closely monitored.
CONDITIONS
Brief Title
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
Research Team
A
Arthur Senigout
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here